| abstract |
Compounds of Formula I are provided, wherein R2, R3, R13, L and D2 are as defined in the specification, which are useful in the treatment and / or in the prevention of diseases or disorders mediated by deficient levels of activity of glucokinase or which can be treated by activating glucokinase, including, but not limited to, diabetes mellitus, impaired glucose tolerance, IFG (impaired fasting glucose) and IFG (impaired fasting blood glucose), as well as other diseases and disorders such as those discussed herein. |